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   ABSTRACT   
  Introduction      An ACR/EULAR task force released new 
criteria to classify rheumatoid arthritis at an early stage. 
This study evaluates the diagnostic performance of 
these criteria and algorithms by van der Helm and Visser 
in REACH.   
  Methods    Patients  with  symptoms  ≤12 months 
from REACH were used. Algorithms were tested on 
discrimination, calibration and diagnostic accuracy of 
proposed cut-points. Two patient sets were deﬁ  ned to 
test robustness; undifferentiated arthritis (UA) (n=231) 
and all patients including those without synovitis 
(n=513). The outcomes evaluated were methotrexate 
use and persistent disease at 12 months.   
  Results      In UA patients all algorithms had good areas 
under the curve 0.79, 95% CI 0.73 to 0.83 for the ACR/
EULAR criteria, 0.80, 95% CI 0.74 to 0.87 for van der 
Helm and 0.83, 95% CI 0.77 to 0.88 for Visser. All 
calibrated well. Sensitivity and speciﬁ  city were 0.74 and 
0.66 for the ACR/EULAR criteria, 0.1 and 1.0 for van der 
Helm and 0.59 and 0.93 for Visser. Similar results were 
found in all patients indicating robustness.   
  Conclusion      The ACR/EULAR 2010 criteria showed 
good diagnostic properties in an early arthritis cohort 
reﬂ  ecting daily practice, as did the van der Helm and 
Visser algorithms. All were robust. To promote uniformity 
and comparability the ACR/EULAR 2010 criteria should be 
used  in  future  diagnostic  studies.      
  Recently an American College of Rheumatology/
European League Against Rheumatism (ACR/
EULAR) task force released new classiﬁ  cation crite-
ria for rheumatoid arthritis (RA) at an early stage.  1   
These criteria might also have diagnostic value 
early in the disease process although this has not 
yet been evaluated. Early diagnosis is important 
to improve patient outcome by early treatment to 
prevent joint damage and functional impairment.  2   
  The previous classiﬁ  cation criteria for RA (the 
1987 ACR criteria) proved inadequate in the early 
stages of disease.  3     4   This led to the development 
of other diagnostic algorithms.  5     6   These algorithms 
showed good diagnostic performance and identi-
ﬁ  ed patients at an early stage of the disease.  7    –    9   
  Diagnostic algorithms tend to be overopti-
mistic in their capabilities when only tested in 
the population they were derived from.  10   For 
instance, if a high erythrocyte sedimentation rate 
(ESR) is an important predictor for RA but in the 
derivation cohort by chance only a few patients 
had a high ESR, the data-driven way in which 
these algorithms are build will not identify this 
  predictor. Therefore before use in practice the 
discriminative abilities of such algorithms should 
be tested in another cohorts with similar patients 
(similar incidence rate). In addition, the robust-
ness of algorithms to variation of incidence rates 
can be tested in cohorts with different previous 
disease probabilities.  11    –    13   
  We aim to evaluate the diagnostic performance 
of the ACR/EULAR 2010 criteria and two diagnos-
tic algorithms simultaneously to predict metho-
trexate use or persistent disease in the Rotterdam 
Early Arthritis Cohort (REACH). In addition, we 
will test robustness after deﬁ  ning two patient sets 
in the same cohort resulting in different previous 
probabilities of developing RA. 
  METHODS 
  Diagnostic  algorithms 
  Three diagnostic algorithms were evaluated. The 
ﬁ   rst is the new ACR/EULAR 2010 criteria set.  1   
The other two, the algorithms by van der Helm 
and the one by Visser, are existing, well-known 
models.  5     6     
  Validation  cohort 
  Clinical data used were from REACH. This ongoing, 
prospective, inception cohort study was set up in the 
greater Rotterdam area in July 2004. Patients were 
recruited either via their general practitioner, or via 
the outpatient rheumatology clinic of three hospitals 
at ﬁ  rst consultation. Patients were included in case 
of one or more swollen joint or, in the absence of 
joint swelling, if they had two or more joints with 
pain or loss of movement with two or more of the 
following criteria: morning stiffness for more than 
1 h; unable to clench a ﬁ  st in the morning; pain 
when shaking someone’s hand; pins and needles in 
the ﬁ  ngers; difﬁ  culties wearing rings or shoes; a fam-
ily history of RA; unexplained fatigue for less than 
1 year. Patients were excluded if their symptoms 
resulted from trauma or overexertion, were for over 
12 months, or if they were younger than 16 years. 
  A trained research nurse at the REACH clinic took a 
standardised history and conducted a physical exami-
nation at baseline, 6 and 12 months, including blood 
and urine samples. For the current analysis data from 
baseline and 1 year were used. Physical examina-
tion included the measurement of tender and swol-
len joints, using a 44 joint count. Laboratory variables 
included IgM-rheumatoid factor (ELISA), anti-cyclic 
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citrullinated peptide  (Elia CCP on immunoCAP 250; Phadia Freiburg, 
Germany),  C-reactive protein (local standards) and ESR (local stan-
dards). x-Rays of hands and feet were assessed for bony erosions at 
baseline. For a detailed description of REACH, see Geuskens et al.  14     
  Statistical  analyses 
  To asses overall performance the prediction algorithms were 
tested on discrimination and calibration.  15   Discrimination is the 
ability of an algorithm to differentiate correctly between patients 
with and without the disease. Calibration reveals the ability to 
estimate the probability of the diagnosis for individuals correctly 
by comparing the probability predicted by the algorithm and the 
observed probability. To evaluate discrimination receiver operat-
ing characteristic curves, including corresponding areas under the 
curve (AUC), were calculated. Calibration was evaluated using 
calibration plots and the Hosmer–Lemeshow test.  15   The latter 
indicates good calibration if a non-signiﬁ  cant result appears. To 
assess diagnostic performance of the algorithms sensitivity, speci-
ﬁ  city, positive predictive values (PPV) and negative predictive val-
ues (NPV) were estimated at cut-points proposed for treatment 
initiation among patients at risk of RA. For the ACR/EULAR 2010 
criteria and Visser algorithm a score of 6 or more  1     16   was used and 
for van der Helm a score of 8 or more  5   was used. To test robust-
ness this analysis was repeated among all patients included in 
REACH. This group had a lower previous disease probability by a 
case-mix of synovitis and inﬂ  ammatory joint complaints without 
synovitis. Synovitis was deﬁ  ned as joint swelling. 
  As a classiﬁ  er for correct diagnosis two outcomes were evalu-
ated at 1 year: the use of methotrexate and persistent disease, 
deﬁ  ned as synovitis present at physical examination after 1 year, 
or the use of disease-modifying antirheumatic drugs (DMARD) 
including biological agents. Patients with a deﬁ  nite alternative 
diagnosis such as gout were not classiﬁ  ed as persistent disease. 
A complete case analysis was done.     
  RESULTS 
  Validation  cohort 
  Up to 31 October 2008, 875 patients were referred to REACH and 
had 1-year follow-up. One hundred and 13 patients did not fulﬁ  l 
the inclusion criteria and 31 patients were lost to follow-up at base-
line (see supplementary ﬁ  gure S1, available online only). Patients 
used in the development of the ACR/EULAR 2010 criteria were 
excluded (n=216).  1     Table 1   reports baseline characteristics of all 
patients (n=513). Patients had a mean age of 50 years, 73% were 
women and the median symptom duration was 106 days (range 
1–366 days). At baseline 48% (n=246) presented with synovitis. 
After 1 year, 148 of 513 used methotrexate, of whom 22 did not 
have synovitis at baseline, and 231 of 513 patients had persistent 
disease, of whom 59 did not have synovitis at baseline.     
  Discrimination 
    Table 2   shows AUC of each diagnostic algorithm for both out-
comes. In undifferentiated arthritis (UA) patients (n=231) the 
AUC for methotrexate use were comparable, with overlapping 
95% CI, 0.79 (95% CI 0.73 to 0.83) for the ACR/EULAR 2010 
criteria, 0.80 (95% CI 0.74 to 0.87) for the van der Helm algo-
rithm and 0.83 (95% CI 0.77 to 0.88) for the Visser algorithm. 
For persistent disease the AUC were 0.77 (95% CI 0.71 to 0.85) 
for the ACR/EULAR 2010 criteria, 0.78 (95% CI 0.71 to 0.85) 
for the van der Helm algorithm and 0.77 (95% CI 0.71 to 0.83) 
for the Visser algorithm. In all patients (n=513) the AUC were 
comparable for both outcomes, with slightly better performance 
of the van der Helm algorithm; 0.88 (95% CI 0.84 to 0.91) and 
0.83 (95% CI 0.79 to 0.87).     
  Calibration 
  Calibration plots of all diagnostic algorithms are shown in 
  ﬁ  gure S2 (see supplementary ﬁ  gure S2, available online only). In 
UA patients (n=513) calibration was worse than in all patients, 
although the Hosmer–Lemeshow test was not signiﬁ  cant for 
any of the calibration plots. All algorithms calibrated well in all 
patients (n=513), conﬁ  rmed by the Hosmer–Lemeshow test.   
    Evaluating diagnostic performance using proposed cut-points 
  To identify patients in need of treatment proposed cut-points 
were tested in UA patients. The ACR/EULAR criteria showed 
a sensitivity of 0.74 (95% CI 0.65 to 0.82) and a speciﬁ  city of 
0.66 (95% CI 0.54 to 0.76), with the cut-point of 6 or higher 
using methotrexate as a classiﬁ  er for correct diagnosis (  table 3  ). 
The Visser algorithm and the van der Helm algorithm had a 
lower sensitivity, 0.47 and 0.59 for the Visser algorithm for both 
outcomes and 0.08 and 0.10 for the van der Helm algorithm. 
Speciﬁ  city was higher: 0.93 for the Visser algorithm and 1.0 for 
the van der Helm algorithm.   
  The PPV is the probability that a patient has the disease if the 
test is positive. The van der Helm algorithm had the highest PPV; 
1.0. The NPV is the opposite probability and was highest for the 
ACR/EULAR criteria with 0.63 for methotrexate use and 0.46 for 
persistent disease, slightly higher than the Visser algorithm.     
  DISCUSSION 
  The results of our study show that the new ACR/EULAR 2010 
criteria could aid diagnostics in early arthritis patients. They had 
good overall performance, with a sufﬁ  ciently high AUC and 
good performance of the proposed cut-point of 6 for persistent 
disease, which could be considered RA. The other algorithms 
performed well when tested for discriminatory properties 
 Table  1        Patient characteristics for each patient set   
   UA  (n=231)    All patients (n=513) 
Women (%) 68 73
Age, years (mean, SD) 53 (14) 50 (14)
SJC (median, range) 4 (1–38) 0 (0–38)
TJC (median, range) 7 (0–42) 6 (0–42) mv=2
RF positive (%) 35% 26%
Anti-CCP positive (%) 28% mv=6 19% mv=10
ESR, mm/h (median, range) 18 (1–103) mv=7 14 (0–103) mv=15
CRP, mg/l (median, range) 6 (1–180) mv=16 5 (1–180) mv=40
Erosions (%) 9% mv=4 4% mv=9
RA, according to 1987 ACR criteria 29% mv=3 14% mv=5
RA, according to 2010 ACR/EULAR 
criteria
45% mv=12 58% mv=6
Persistent arthritis at 1 year 45% mv=9 71% mv=3
      ACR, American College of Rheumatology; CCP, cyclic citrullinated protein; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; EULAR, European League 
Against Rheumatism; mv, missing values; RA, rheumatoid arthritis; RF, rheumatoid 
factor; SJC, swollen joint count; TJC, tender joint count; UA, undifferentiated arthritis.     
 Table  2     Area under the receiver operating characteristic curves with 
95% CI for each algorithm and each patient set   
  ACR/EULAR 2010 Van der Helm Visser
Outcome methotrexate use
  UA patients 0.79 (0.73 to 0.85) 0.80 (0.74 to 0.87) 0.83 (0.77 to 0.88)
  All patients 0.79 (0.75 to 0.83) 0.88 (0.84 to 0.91) 0.80 (0.76 to 0.85)
Outcome persistent disease
  UA patients 0.77 (0.71 to 0.85) 0.78 (0.71 to 0.85) 0.77 (0.71 to 0.83)
 All  patients 0.74 (0.70 to 0.78) 0.83 (0.79 to 0.87) 0.74 (0.70 to 0.79)
   UA,  undifferentiated  arthritis.   
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(AUC and calibration), although the van der Helm algorithm 
failed to detect cases at the proposed cut-point. To promote uni-
formity and comparability of studies we would suggest using 
the ACR/EULAR 2010 criteria in future diagnostic studies. 
  The cut-point of 6 in the ACR/EULAR 2010 criteria was well 
chosen and showed good diagnostic performance, even though 
it was not intended for diagnostic purposes.  1   Choosing a cut-
point is a trade-off between harm of treatment in non-cases 
(overtreatment) and harm of no treatment in cases (undertreat-
ment).  13     17   Ideally a cut-point has a high sensitivity to prevent 
undertreatment and a high speciﬁ  city to prevent overtreatment. 
However, a high speciﬁ  city is often accompanied by a low to 
moderate sensitivity and vice versa. For the ACR/EULAR 2010 
criteria both sensitivity and speciﬁ   city were approximately 
70%. Using this cut-point of 6 to start treatment, in this study 
30% of persistent patients would not be treated, whereas 30% 
of the non-persistent patients would have been. Lowering the 
cut-point to 4 increases sensitivity to 0.92 at the cost of speciﬁ  c-
ity (0.33). Increasing it to 7 had a sensitivity of 0.53 and a speci-
ﬁ  city of 0.85. Perhaps creating a low, intermediate and high-risk 
group for disease using dual cut-points would enable treatment 
with different intensities. 
  The cut-point of 6 was chosen using the AUC of three cohorts, 
including our own. In this study the AUC for methotrexate use, 
0.79, was similar to that in the derivation article (0.66–0.82), 
indicating consistency. It was also similar (0.77) for persistent 
disease. It could be argued that this is a direct result of the use 
of our data in the derivation cohort. However, the decision to 
use 6 as cut-point was based on expert opinion and two other 
cohorts. Furthermore, patients included in the derivation of the 
ACR/EULAR 2010 criteria were removed from analyses. 
  The strengths of our study include the heterogeneity of 
patients’ subsets to test robustness of the algorithms and simul-
taneous evaluation of three diagnostic algorithms in one study 
sample. We showed that the ACR/EULAR criteria and both algo-
rithms were robust in a case-mix of synovitis and non-synovitis 
patients. Calibration was good for all algorithms, but not  perfect. 
Calibration and robustness have not been evaluated before by 
others, but discrimination was. The van der Helm algorithm 
showed AUC of 0.82–0.88 and the Visser algorithm an AUC of 
0.70, both similar to the AUC in the present study.  7    –    9   
  This study should be interpreted in the light of current 
developments in diagnostic research in RA. Current diagnostic 
studies within RA are faced with deﬁ  ning a suitable outcome. 
We deﬁ   ned two outcomes; methotrexate use similar to the 
  deﬁ   nition of the ACR/EULAR 2010 and persistent disease 
(either synovitis or DMARD use at 12 months).  1   This may have 
led to misclassiﬁ  cation in two ways. Patients could be classiﬁ  ed 
as true positive because they were still using methotrexate or 
other DMARD at 12 months, whereas in fact some patients 
may not need treatment. Likewise, patients may have had epi-
sodes of arthritis with no episode or DMARD use at 12 months, 
while later on they developed persistent arthritis. 
  In conclusion, the new ACR/EULAR 2010 criteria showed 
good diagnostic properties in an early arthritis cohort reﬂ  ecting 
daily clinical practice, as did the van der Helm and Visser algo-
rithms. All were robust. To promote uniformity and compara-
bility we would suggest using the ACR/EULAR 2010 criteria in 
future diagnostic studies. 
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 Table  3        Sensitivity, speciﬁ  city, and PPV and NPV at the proposed 
cut-points in UA patients   
 
 Sensitivity 
(95% CI) 
 Speciﬁ  city 
(95% CI) 
 PPV 
(95% CI) 
 NPV 
(95% CI) 
methotrexate use
   ACR/EULAR 
2010 criteria
0.74 
(0.65 to 0.82)
0.66 
(0.54 to 0.76)
0.76 
(0.67 to 0.83)
0.63 
(0.52 to 0.73)
    van der Helm 
algorithm
0.10 
(0.05 to 0.17)
1.0 
(0.95 to 1.0)
1.0 
(0.74 to 1.0)
0.43 
(0.35 to 0.50)
 Visser  algorithm 0.59 
(0.50 to 0.68)
0.93 
(0.85 to 0.97)
0.92 
(0.84 to 0.97)
0.62 
(0.53 to 0.71)
Persistent disease
   ACR/EULAR 
2010 criteria
0.69 
(0.61 to 0.76)
0.72 
(0.59 to 0.83)
0.87 
(0.80 to 0.92)
0.46 
(0.35 to 0.56)
    van der Helm 
algorithm
0.08 
(0.05 to 0.14)
1.0 
(0.93 to 1.0)
1.0 
(0.75 to 1.0)
0.27 
(0.21 to 0.34)
 Visser  algorithm 0.47 
(0.39 to 0.55)
0.93 
(0.84 to 0.98)
0.95 
(0.87 to 0.99)
0.40 
(0.31 to 0.48)
      ACR, American College of Rheumatology; EULAR, European League Against 
Rheumatism; NPV, negative predictive value; PPV, positive predictive value, 
UA, undifferentiated arthritis.     
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